Trial Profile
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Adverse reactions
- 17 Apr 2023 Planned End Date changed from 1 Nov 2024 to 31 Dec 2024.
- 17 Apr 2023 Planned primary completion date changed from 1 Nov 2024 to 31 Dec 2024.
- 28 Oct 2022 Planned End Date changed from 1 Sep 2024 to 1 Nov 2024.